Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anthony W. DeFusco"'
Autor:
Johan A. Kers, Robert E. Sharp, Anthony W. Defusco, Jae H. Park, Jin Xu, Mark E. Pulse, William J. Weiss, Martin Handfield
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
Lantibiotics offer an untapped pipeline for the development of novel antibiotics to treat serious Gram-positive (+) infections including Clostridium difficile. Mutacin 1140 (MU1140) is a lantibiotic produced by Streptococcus mutans and acts via a nov
Externí odkaz:
https://doaj.org/article/b817fd7f62a14cda95a6d257a5f10e9a
Autor:
N. V. Rajeshkumar, Martin Handfield, Johan A. Kers, Jae H. Park, Scott Moncrief, Anthony W. Defusco
Publikováno v:
Toxicology and Applied Pharmacology. 374:32-40
Clostridium difficile associated disease (CDAD) is the leading infectious cause of antibiotic-associated diarrhea and colitis in the United States. Both the incidence and severity of CDAD have been increased over the past two decades. We evaluated th
Autor:
Martin Handfield, Jae H. Park, Mark Pulse, William J. Weiss, Anthony W. Defusco, Johan A. Kers
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Lantibiotics present an attractive scaffold for the development of novel antibiotics. We report here a novel lantibiotic for the treatment of Clostridium difficile infection. The lead compounds were selected from a library of over 700 single- and mul
Autor:
Anthony W. Defusco, Robert Eryl Sharp, Jin Xu, Jae H. Park, Martin Handfield, William J. Weiss, Mark Pulse, Johan A. Kers
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
Frontiers in Microbiology
Frontiers in Microbiology
Lantibiotics offer an untapped pipeline for the development of novel antibiotics to treat serious Gram-positive (+) infections including Clostridium difficile. Mutacin 1140 (MU1140) is a lantibiotic produced by Streptococcus mutans and acts via a nov
Autor:
Johan A. Kers, Sheela Muley, Jeffrey Colbeck, Melissa Mayo, R. Eryl Sharp, Jae H. Park, Anthony W. Defusco, Yihui Zhu, Martin Handfield
Publikováno v:
Chemical biologydrug design. 92(6)
Lantibiotics represent a large untapped pipeline of attractive scaffolds for the development of novel antibiotics. Saturation mutagenesis was employed to substitute every amino acid of a lantibiotic called mutacin 1140 (MU1140), creating an unbiased
OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections
Autor:
Martin Handfield, Jae H. Park, Johan A. Kers, William J. Weiss, Jin Xu, Anthony W. Defusco, Mark Pulse
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0197467 (2018)
Lantibiotics continue to offer an untapped pipeline for the development of novel antibiotics. We report here the discovery of a novel lantibiotic for the treatment of C. difficile infection (CDI). The leads were selected from a library of over 300 mu
Autor:
Johan A. Kers, R. Eryl Sharp, Sheela Muley, Melissa Mayo, Jeffrey Colbeck, Yihui Zhu, Anthony W. DeFusco, Jae H. Park, Martin Handfield
Publikováno v:
Chemical Biology & Drug Design. 92:i-i
Autor:
Johan A Kers, Anthony W DeFusco, Jae H Park, Jin Xu, Mark E Pulse, William J Weiss, Martin Handfield
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0197467 (2018)
Lantibiotics continue to offer an untapped pipeline for the development of novel antibiotics. We report here the discovery of a novel lantibiotic for the treatment of C. difficile infection (CDI). The leads were selected from a library of over 300 mu
Externí odkaz:
https://doaj.org/article/8576e0e2154a45a69a25cf4db2f4e489